```markdown
---
application_number: NDA 208742
sponsor: Ocular Therapeutix, Inc.
product: DEXTENZA (dexamethasone ophthalmic insert), 0.4 mg, for intracanalicular use
contact:
  name: Judit Milstein
  title: Chief, Project Management Staff
  phone: 301-796-0763
correspondence_from:
  name: Renata Albrecht, MD
  title: Director
  division: Division of Transplant and Ophthalmology Products
  office: Office of Antimicrobial Products
  center: Center for Drug Evaluation and Research
proprietary_name:
  status: Acceptable pending approval
  dates:
    - April 12, 2017
    - January 27, 2016
inspection_fei: '3008477155'
resubmission_due: 1 year from letter date
legal_status: Not legally marketable until FDA issues written approval
---

## Critical Data

- **Application Number:** NDA 208742  
- **Sponsor:** Ocular Therapeutix, Inc.  
- **Product:** DEXTENZA (dexamethasone ophthalmic insert), 0.4 mg  
- **Dosage Form:** Intracanalicular ophthalmic insert  
- **FEI Number:** 3008477155  
- **Contact:** Judit Milstein, Chief, Project Management Staff, 301-796-0763  
- **Proprietary Name:** DEXTENZA  
- **Proprietary Name Status:** Acceptable pending approval  
- **Resubmission Instructions:** Complete response required within 1 year  
- **Prescribing Info Format:** Structured Product Labeling (SPL)  
- **Legal Marketing Status:** Not legally marketable until written FDA approval  
- **Reviewer:** Renata Albrecht, MD, Director, Division of Transplant and Ophthalmology Products  

---

# COMPLETE RESPONSE LETTER  
**Application Number:** NDA 208742  
**Sponsor:** Ocular Therapeutix, Inc.  
**Product:** DEXTENZA (dexamethasone ophthalmic insert), 0.4 mg, for intracanalicular use  

---

## Cover Letter

**To:**  
Eric P. Ankerud, JD  
Executive Vice President, Regulatory, Quality and Compliance  
Ocular Therapeutix, Inc.  
34 Crosby Drive, Suite 105  
Bedford, MA 01730  

**From:**  
Renata Albrecht, MD  
Director  
Division of Transplant and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research  

---

## Application and Amendment Acknowledgment

We acknowledge receipt of your:

- New Drug Application (NDA) dated and received September 24, 2015  
- Amendment dated January 19, 2017 (constituting a complete response to our July 21, 2016 action letter)  
- Amendment dated July 10, 2017 (not reviewed for this action)

You may incorporate applicable sections of the July 10, 2017 amendment by specific reference as part of the response to the deficiencies cited below.

---

## Summary Decision

We have completed our review and determined that we **cannot approve this application in its present form**. Reasons and recommendations are provided below.

---

## PRODUCT QUALITY / FACILITIES INSPECTION

The methods and facilities for manufacturing, processing, packing, or holding the drug product must comply with current good manufacturing practices (21 CFR 210 and 211).

- During inspection of Ocular Therapeutix, Inc. (FEI#3008477155), deficiencies were conveyed to facility representatives.
- Satisfactory resolution of these deficiencies is required prior to approval.  
- See correspondence issued jointly by the New England District Office and the Office of Process and Facilities on July 10, 2017.

---

## PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate.

We encourage you to:

- Review the labeling resources on the PLR Requirements and Pregnancy and Lactation Labeling Final Rule websites  
- Use the SRPI (Selected Requirements for Prescribing Information) checklist  
- Ensure your response includes updated content of labeling [21 CFR 314.50(l)(1)(i)] in Structured Product Labeling (SPL) format as described at:  
  [FDA SPL Website](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

---

## PROPRIETARY NAME

Refer to correspondence from the Division of Medication Errors and Analysis:

- April 12, 2017 – Proprietary name "DEXTENZA" found acceptable pending approval in this cycle  
- January 27, 2016 – Proprietary name "DEXTENZA" acceptable pending application approval  
- Please resubmit the proposed proprietary name in your response

---

## SAFETY UPDATE

Include a safety update as per 21 CFR 314.50(d)(5)(vi)(b):

- Include data from all nonclinical and clinical studies/trials of the product  
- Include data regardless of indication, dosage form, or dose level

---

## ADDITIONAL COMMENTS (Not Approvability Issues)

1. Update visual inspection controls:  
   - Include acceptable quality limits (AQL)  
   - Provide justification for those limits

2. Provide a comprehensive list of:  
   - Manufacturing, equipment, and procedural changes  
   - Controls implemented since previous resubmission  
   - Updated batch manufacturing instructions  
   - New production records supporting this NDA

---

## ADDITIONAL COMMENTS

1. Amendment dated June 13, 2016:  
   - Updates to critical material attributes, in-process controls, and quality limits  
   - Test data not provided for registration, stability, and proposed PQ batches  
   - Provided examples (Lot No. 03241602, 04211605) lacking complete records  
   - Provide:
     - Batch manufacturing records  
     - In-process test results

2. Scale-up strategy:  
   - No full information provided beyond current commercial scale  
   - Complexity, manual operations, and custom equipment noted  
   - Scale-up beyond current stated scale must be submitted as a Prior Approval Supplement (PAS)

---

## OTHER

### Resubmission Requirements

- Submit a fully responsive application within one year of this letter  
- Clearly identify cover letter with "**RESUBMISSION**" in large, bold font  
- State clearly that it is a complete response  
- A partial response will not initiate a new review cycle

### Meetings

You may request a meeting or teleconference to discuss next steps.  

Guidance Documents:  
- March 2015 — [Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm437431.pdf)  
- May 2009 — [Formal Meetings Between FDA and Sponsors or Applicants](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM153222.pdf)

---

## LEGAL MARKETING STATUS

The drug product may not be legally marketed until written notification of approval is provided.

---

## Contact

If you have questions, contact:

**Judit Milstein**  
Chief, Project Management Staff  
Phone: 301-796-0763

---

## Signature

Renata Albrecht, MD  
Director  
Division of Transplant and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research
```